Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

Sanofi (SNY) and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating invasive pneumococcal disease (“IPD”) in pediatric and adult patient populations.The latest deal builds on the existing collaboration between SNY and SK bioscience to develop and commercialize a 21-valent PCV (PCV21) for the pediatric patient population.Sanofi also said that the companies commenced a phase III p ...